CA2220538A1 - .beta.-adrenergic agonists - Google Patents

.beta.-adrenergic agonists Download PDF

Info

Publication number
CA2220538A1
CA2220538A1 CA002220538A CA2220538A CA2220538A1 CA 2220538 A1 CA2220538 A1 CA 2220538A1 CA 002220538 A CA002220538 A CA 002220538A CA 2220538 A CA2220538 A CA 2220538A CA 2220538 A1 CA2220538 A1 CA 2220538A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002220538A
Other languages
English (en)
French (fr)
Inventor
Robert Lee Dow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Robert Lee Dow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Robert Lee Dow filed Critical Pfizer Inc.
Priority to CA002220538A priority Critical patent/CA2220538A1/en
Priority to EP95915993A priority patent/EP0828712A1/en
Priority to PCT/IB1995/000342 priority patent/WO1996035670A1/en
Priority to JP8533902A priority patent/JPH11504648A/ja
Priority to CN96105900A priority patent/CN1144801A/zh
Publication of CA2220538A1 publication Critical patent/CA2220538A1/en
Priority to FI974170A priority patent/FI974170A/fi
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
CA002220538A 1995-05-10 1995-05-10 .beta.-adrenergic agonists Abandoned CA2220538A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
EP95915993A EP0828712A1 (en) 1995-05-10 1995-05-10 Beta-adrenergic agonists
PCT/IB1995/000342 WO1996035670A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS
JP8533902A JPH11504648A (ja) 1995-05-10 1995-05-10 β−アドレナリン作動性アゴニスト
CN96105900A CN1144801A (zh) 1995-05-10 1996-05-07 β-肾上腺素能兴奋剂
FI974170A FI974170A (fi) 1995-05-10 1997-11-07 B-adrenergisiä agonisteja

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002220538A CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
PCT/IB1995/000342 WO1996035670A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS

Publications (1)

Publication Number Publication Date
CA2220538A1 true CA2220538A1 (en) 1996-11-14

Family

ID=25679804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002220538A Abandoned CA2220538A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists

Country Status (6)

Country Link
EP (1) EP0828712A1 (ja)
JP (1) JPH11504648A (ja)
CN (1) CN1144801A (ja)
CA (1) CA2220538A1 (ja)
FI (1) FI974170A (ja)
WO (1) WO1996035670A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69735433D1 (de) 1996-11-14 2006-05-04 Pfizer Verfahren zur herstellung von substituierten pyridinen
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
AU735249B2 (en) * 1997-07-03 2001-07-05 Asahi Kasei Kabushiki Kaisha Novel tricyclic compounds having saturated rings and medicinal compositions containing the same
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
DK1277736T3 (da) 2000-04-28 2007-10-01 Asahi Kasei Pharma Corp Hidtil ukendte bicykliske forbindelser
KR100622461B1 (ko) 2001-10-25 2006-09-19 아사히 가세이 파마 가부시키가이샤 2환식 화합물
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
CN102171191A (zh) 2008-10-09 2011-08-31 旭化成制药株式会社 吲唑衍生物
CA2740772A1 (en) 2008-10-09 2010-04-15 Asahi Kasei Pharma Corporation Indazole compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
EP0105053B1 (en) * 1982-10-01 1988-01-20 Merck & Co. Inc. Aralkylaminoethanol heterocyclic compounds
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5726192A (en) * 1992-12-29 1998-03-10 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions

Also Published As

Publication number Publication date
CN1144801A (zh) 1997-03-12
FI974170A0 (fi) 1997-11-07
JPH11504648A (ja) 1999-04-27
FI974170A (fi) 1997-11-07
WO1996035670A1 (en) 1996-11-14
EP0828712A1 (en) 1998-03-18

Similar Documents

Publication Publication Date Title
US5977124A (en) β-adrenergic agonists
US5859044A (en) β-adrenergic agonists
US5843972A (en) Heterocyclic β-adrenergic agonists
US6706743B2 (en) β3 adrenergic receptor agonists and uses thereof
MXPA97008621A (en) Agonistasó-adrenergicos, compositions that contain and use of mis
MXPA97002601A (en) Agonistasó-adrenergicos heterocicli
CA2220538A1 (en) .beta.-adrenergic agonists
US5767133A (en) Secondary amines as antidiabetic and antiobesity agents
US5627200A (en) β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
PL196943B1 (pl) Lecznicza pochodna biarylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
CZ458390A3 (en) Diamides of pyrimidine-4,6-dicarboxylic acid, process of their preparation and medicaments based thereon
US20080300290A1 (en) Novel Beta-Agonists, Process for Their Preparation and Their Use as Medicaments
US6001856A (en) β-adrenergic agonists to reduce a wasting condition
US20050075323A1 (en) Beta3 adrenergic receptor agonists and uses thereof
US4551460A (en) Pyrido[2,1-b]quinazoline derivatives useful as agents for treatment of allergic conditions and vascular disorders involving thrombosis
AU4747599A (en) Intermediates for the preparation of beta-adrenergic agonists
JPH0314562A (ja) 新規なアルキレンジアミン誘導体およびグルタミン酸遮断剤
KR100556559B1 (ko) 2-(4-(4-(4,5-디클로로-2-메틸이미다졸-1-일)부틸)-1-피페라지닐)-5-플루오로피리미딘, 이것의 제조 방법 및 이것의치료적 용도
MXPA97005815A (es) Agonistasó-adrenergicos
US20100098629A1 (en) Novel Amides Acting on the Adenosine Receptors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead